X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JUV-161, which was identified by Juvena’s AI-driven drug discovery and development platform, has demonstrated an ability to restore muscle fiber formation, counter muscle atrophy & enhance muscle strength. It is being evaluated in preclinical studies for the treatment of DM1.
Lead Product(s): JUV-161
Therapeutic Area: Genetic Disease Product Name: JUV-161
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
JUV-161 is the only protein-based therapeutic being developed for a rare muscle-wasting disease, myotonic dystrophy type 1 (DM1).
Lead Product(s): JUV-161
Therapeutic Area: Genetic Disease Product Name: JUV-161
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mubadala Capital
Deal Size: $41.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 08, 2022
Details:
The grant will fund the advancement of Juvena's lead program, fusion protein therapeutic JUV-161, for the treatment of the rare muscle-wasting disease, DM1, through initial IND-enabling studies and a pre-IND FDA meeting in the next 12-16 months.
Lead Product(s): JUV-161
Therapeutic Area: Genetic Disease Product Name: JUV-161
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: California Institute of Regenerative Medicine
Deal Size: $3.9 million Upfront Cash: Undisclosed
Deal Type: Funding February 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
